The present invention relates to conjugates comprising B- and T-cell epitopes, vaccine compositions comprising said conjugates, their use in the prevention and treatment of cancer, such as prostate cancer, as well as kits comprising the conjugates and/or vaccine compositions. Also claimed are particular T-cell epitope-containing antigenic peptides, and nucleic acids encoding them and constructs and vectors comprising such nucleic acids.

This invention is directed to compositions, vaccines, and methods for the manufacture and administration of immunogenic compositions containing one or more antigenic regions of a pathogen coupled via hydrazine-PEG-hydrazine linkers to a carrier, and to immunogenic compositions that are vaccines. Immunogenic compositions of the invention may contain multiple epitopes obtained or derived from multiple variants of the same or different infectious pathogens which may be bacterial and/or viral. The invention is also directed to methods for the manufacture or immunogenic composition, and methods for the prevention and treatment of pathogenic infections by administration of immunogenic compositions disclosed herein.

The present invention is directed towards conjugates comprising fragments of the capsular polysaccharide of Type III Group B Streptococcus (GBS). Suitable fragments may be produced synthetically or by depolymerisation of native polysaccharide.

A carrier molecule composition. Specific implementations may include: a carrier molecule including at least one cell penetrating peptide (CPP) where the carrier molecule may include at least one hydrophobic domain and where the carrier is non-covalently associated with a biologically active molecule in one of a micelle and a liposome.

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Provided are methods for sensitizing gastrin-associated tumors and/or cancers in subjects to inducers of humoral and cellular immune responses. In some embodiments, the methods relate to administering compositions that have anti-gastrin antibodies, gastrin peptides, and/or nucleic acids that inhibit expression of gastrin gene products to subjects. Also provided are methods for preventing, reducing, and/or eliminating the formation of fibroses associated with tumors and/or cancers, and methods for treating gastrin-associated tumors and/or cancers that include administering to subjects in need thereof a first agent that provides and/or induces an anti-gastrin humoral or cellular immune response in the subject and a second agent that includes one or more stimulators of cellular immune responses against the tumors and/or cancers.

This invention is directed to immunogenic composition, conjugates, virus-like particles (VLP) compositions, vaccines and methods directed to the treatment and/or prevent of infection by Human Papillomavirus.

The invention provides methods or compositions for treating cancer using an immune cell, e.g, a T-cell, e.g., a CAR T-cell, optionally in combination with a superantigen conjugate. The invention also provides methods for making immune cells, e.g, T-cells, e.g, CAR T-cells, for use in the treatment of cancer.

A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.

The present invention relates to a synthetic saccharide of general formula (I) that is related to Klebsiella pneumoniae serotype O1, O2, O2ac, and O8 O-polysaccharide and carbapenem-resistant Klebsiella pneumoniae ST258 O-polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae bacteria.